Evidence map›Paper›PMID 40892123›Full record

ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025

Slimming the risks: GLP-1 receptor agonist therapy may reduce in-hospital complications and hospital readmissions rates for hip fractures compared to obese patients not on these medications.

Amelia R Goldstein, Danielle Olson, Phillip Leucht, Nirmal Tejwani, Abhishek Ganta, Sanjit Konda, Kenneth A Egol

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amelia R GoldsteinDepartment of Orthopedic Surgery, New York University Langone Medical Center, New York, USA. amelia.goldstein@nyulangone.org.
Danielle OlsonDepartment of Orthopedic Surgery, New York University Langone Medical Center, New York, USA.
Phillip LeuchtDepartment of Orthopedic Surgery, New York University Langone Medical Center, New York, USA.
Nirmal TejwaniDepartment of Orthopedic Surgery, New York University Langone Medical Center, New York, USA.
Abhishek GantaDepartment of Orthopedic Surgery, New York University Langone Medical Center, New York, USA.
Sanjit KondaDepartment of Orthopedic Surgery, New York University Langone Medical Center, New York, USA.
Kenneth A EgolDepartment of Orthopedic Surgery, New York University Langone Medical Center, New York, USA. kenneth.egol@nyulangone.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo evaluate the impact of prolonged GLP-1 usage on mortality, readmission, incidence of in-hospital complications, and incidence of implant failure following hip fracture surgery across various BMI strata.

methodsA prospective hip fracture registry (2014-2024) at a single institution was used to identify 58 obese patients on prolonged GLP-1 therapy at the time of injury. These patients (Group A) were matched by age, fracture pattern, and comorbidity burden to BMI-based control cohorts: normal (Group B), overweight (Group C), and obese (Group D). Postoperative complication rates, readmissions, and implant failures were compared. Major complications were defined as events needing further procedures, extended hospitalization, or causing significant functional impairment. Minor complications were those managed with minimal treatment. Statistical analysis included ANOVA, chi-square, and post hoc residual testing. Data were analyzed using IBM SPSS Statistics (Version 21.0, Chicago, IL).

resultsA total of 232 patients (58 in each cohort) were included. Minor complication rates differed significantly across cohorts (χ

conclusions≥ 6 months of continuous GLP-1 receptor agonist therapy was associated with a reduction in 30-day and 90-day readmission rates and overall and minor in-hospital complications in obese patients undergoing hip fracture surgery. LEVEL OF EVIDENCE: III.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsHip FracturesObesityPatient ReadmissionPostoperative ComplicationsAgedAged, 80 and overBody Mass IndexFemaleHumansIncidenceMaleMiddle AgedProspective StudiesRegistriesGlucagon-Like Peptide-1 Receptor AgonistsGLP-1 receptor agonist TherapyHip fractureMounjaroOzempic

Identifiers

PMID40892123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.